Michelle Werner brings more than two decades of leadership in pharmaceutical and biotechnology R&D, commercialization, and strategic business development to CRD. She currently serves as Chief Executive Officer of Alltrna and CEO-Partner at Flagship Pioneering, where she advances pioneering tRNA-based therapeutics for high-impact disease areas.
Her early career was anchored in clinical operations at Harvard Medical School’s Oncology Clinical Trials Unit, and she progressed to senior roles at Novartis, AstraZeneca and Bristol Myers Squibb, leading efforts across business development, sales & marketing, and market access for oncology and specialty-disease therapies.
Michelle holds a B.A. in Biology & Anthropology from University of Pennsylvania and an MBA from London Business School. Outside the boardroom, she is a dedicated wife and mother of three, an active advocate within the rare-disease community, and serves on the board of the non-profit Rare Disease Renegades.
Her deep experience in both translational science and commercialization, coupled with her personal commitment to rare-disease families, makes her a strong addition to CRD’s mission to accelerate advanced therapies to patients in need.
Cure Rare Disease, a non-profit organization (Tax ID number 82-2473513), is qualified as a tax-exempt organization under section 501(c)(3) of the IRS and has been designated as a “public charity” under section 170.
